Welcome to team Large Molecule, a team dedicated to servicing organisations within the Biotechnology space. This team’s area covers therapeutics which are produced using a living cell. In 2020, the global Biotechnology market valued at USD 752.88 billion and is forecasted to reach an astonishing USD 2.44 trillion by 2028. Large Molecule is the largest team at Mantell Associates and an enormously busy division led by Ollie Masson. He works closely with Onur Dilek, Fernand Desjarlais, and Michael Selwood. Until 2022, this team focused exclusively on CDMO’s within the Large Molecule space although has since grown and moved outside of this, now working with Innovator companies who produce their own assets.
The Pharmaceutical & Life Sciences landscape has traditionally been dominated by Pharmaceuticals, Chemicals and OTC medicines, although the discovery of biological treatments grown inside living cells has been one of the greatest technical advancements in human history. As a result of this, the Large Molecule arena is now growing faster than its Small Molecule counterpart, although still has a very long way to go before it takes the lead in terms of total market value.
The COVID-19 pandemic has accelerated the growth of the industry, with many of our clients taking on large contracts to develop and manufacture lifesaving vaccines from pharmaceutical giants such as AstraZeneca and Johnson & Johnson. Other clients we work with also produce their own vaccines and biological treatments. The USA accounts for by far the largest portion of Large Molecule’s clientele, although there is still a significant presence in Europe and more recently, Asia, who are seeing exciting growth too.
Currently, the production of COVID-19 vaccines, mRNA therapeutics and Cell & Gene Therapy are spearheading the growth in the industry and accounted for a large base of Mantell Associates' work in 2021. Through this, we are now proudly working with the most exciting names in the Large Molecule CDMO space in both Europe & the US. Our clients are not just manufacturing bulk drug products for their partners but now taking on contracts earlier on in the development process, putting themselves at the heart of the innovation and refining the way things are done at scale.
As far as appointments go, the Large Molecule team leaves no stone unturned and covers everything; including Commercial, Manufacturing, Operations, Project Management, Quality, Regulatory Affairs, IT or even Finance. These range from mid-level all the way through to C-Suite, including Board Appointments. We have enjoyed a very successful 2022 so far with many successful appointments across all these areas.
For any prospective clients working with the Large Molecule team at Mantell Associates, we do not take a ‘one size fits all approach’ and you can expect a bespoke, tailored service based on your business requirements. To do this, we leverage our impressive technical expertise, second-to-none network and deep industry knowledge. Our approach is not just that of a vacancy filler, but where we build meaningful relationships with the people and organisations within our respective field. Together, we will achieve long term, sustainable growth with our clients which then broadens access to complex medicines!
